Morgan Stanley Has Lowered Expectations for Silence Therapeutics (NASDAQ:SLN) Stock Price

Silence Therapeutics (NASDAQ:SLN) had its price target cut by Morgan Stanley from $49.00 to $45.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock.

SLN has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, January 29th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. The Goldman Sachs Group reduced their price objective on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research note on Tuesday. Chardan Capital restated a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a report on Tuesday, December 10th. Finally, BMO Capital Markets dropped their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $40.67.

Silence Therapeutics Trading Down 2.3 %

Silence Therapeutics stock opened at $4.38 on Wednesday. The stock has a fifty day moving average price of $5.53 and a 200 day moving average price of $11.58. Silence Therapeutics has a 52 week low of $4.06 and a 52 week high of $27.72. The firm has a market capitalization of $130.94 million, a P/E ratio of -2.79 and a beta of 1.05.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SLN. Woodline Partners LP raised its position in shares of Silence Therapeutics by 22.6% during the 4th quarter. Woodline Partners LP now owns 498,732 shares of the company’s stock worth $3,431,000 after purchasing an additional 91,829 shares during the period. Two Sigma Advisers LP lifted its stake in Silence Therapeutics by 18.6% in the fourth quarter. Two Sigma Advisers LP now owns 98,800 shares of the company’s stock valued at $680,000 after buying an additional 15,500 shares during the last quarter. Redmile Group LLC grew its position in shares of Silence Therapeutics by 26.3% during the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after acquiring an additional 500,000 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Silence Therapeutics by 35.3% during the 4th quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock valued at $4,356,000 after purchasing an additional 165,300 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Silence Therapeutics by 50.5% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 128,990 shares of the company’s stock valued at $887,000 after buying an additional 43,289 shares during the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.